Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QT/QTc evaluation of AZD5672 vs placebo with moxifloxacin positive control in healthy male volunteers
2009-011044-20Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of azd5672 in rheumatoid arthritis (RA) (4 arms), sponsored by AstraZeneca. Primary endpoint: Change in time-matched QTcF intervals with AZD5672 600 mg vs placebo. Started Apr 2009; status: completed.
02
Drugs
azd5672
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2009-011044-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011044-20.